Seth Harmon
Director of Finance/CFO at VIRIDIAN THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Seth Harmon is currently the Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. Prior to his current position, he served as the Chief Financial Officer at BioNTech SE from 2020 to 2023.
Before that, he was the Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed his undergraduate degree at Bowdoin College and holds a graduate degree in MBA from Northeastern University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-11-09 | 0 ( -.--% ) | - $ | 2024-03-30 |
Seth Harmon active positions
| Companies | Position | Start |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Director of Finance/CFO | 2023-09-11 |
Former positions of Seth Harmon
| Companies | Position | End |
|---|---|---|
| BIONTECH SE | Director of Finance/CFO | 2023-04-30 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 2020-04-30 |
Training of Seth Harmon
| Bowdoin College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BIONTECH SE | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Seth Harmon
